Utility of CYP2D6 Genotyping to Improve the Efficacy and Safety of Tramadol
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Randomized clinical trial to evaluate the utility of CYP2D6 genotyping to improve the
efficacy and safety of tramadol in the treatment of acute postoperative pain.
Phase IV and low-intervention trial To evaluate if the implementation of pharmacogenetics in
clinical practice can help to improve the treatment of acute pain, increasing efficacy and
reducing adverse reactions.
The main evaluation variable: This is a simple study, which does not differ from standard
clinical practice and therefore we do not expect early ending of the study.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Collaborators:
Hospital San Carlos, Madrid Hospital Universitario de Burgos Hospital Universitario Fundación Jiménez Díaz Hospital Universitario La Paz Hospital Universitario Ramon y Cajal Hospital Universitario San Juan de Alicante Puerta de Hierro University Hospital